ClinicalTrials.gg
CompletedNCT02796677Updated Nov 9, 2018Results posted

AMPLIFY - D6571C00001 Duaklir USA Phase III Study

A Phase 3 interventional study of Aclidinium bromide 400 μg/Formoterol Fumarate 12 μg (AB/FF 400/12 μg) and Aclidinium bromide 400 μg (AB 400 μg) in Chronic Obstructive Pulmonary Disease, sponsored by AstraZeneca. Completed at 163 sites in 10 countries. Open to participants aged 40 Years to 130 Years. Per ClinicalTrials.gov, last updated 2018-11-09.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,595
Allocation
Randomized
Ages
40 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing aclidinium bromide in Pulmonary Disease, Chronic Obstructive — none open to participants now, none under way, none of them phase 3. aclidinium bromide · Pulmonary Disease, Chronic Obstructive.

Enrollment
5th of 27
1,595 · median 561
Started
2016
with 1 other
Phase 3
19 of 28
none open now
Registered
25th of 28
by date
Lead sponsor
25 of 28
AstraZeneca

Among the 28 studies testing aclidinium bromide in Pulmonary Disease, Chronic Obstructive, this one is the 5th largest by enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2016, is one of 19 in phase 3, and was the 25th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

None of the 28 studies testing aclidinium bromide in Pulmonary Disease, Chronic Obstructive is open now. The open studies under Pulmonary Disease, Chronic Obstructive, anywhere →

About aclidinium bromide

aclidinium bromide: first FDA approval 2012 (TUDORZA PRESSAIR), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 28 studies testing aclidinium bromide in Pulmonary Disease, Chronic Obstructive as a file.
02

Study summary

This is a multiple dose, randomized, parallel, double-blind, double-dummy, multicenter and multinational Phase III study to determine the efficacy and safety of Aclidinium bromide 400μg/Formoterol Fumarate (AB/FF) 12 μg compared to individual components and TIO (Tiotropium) 18 μg when administered to patients with stable chronic obstructive pulmonary disease (COPD).

Read the detailed description

This study was conducted to assess the bronchodilator efficacy and safety as well as effect on health related quality of life of AB/FF 400/12 μg compared to the individual components (AB 400 μg and FF 12 μg) in COPD patients. The trial duration of 24 weeks allows the assessment of the effect on symptoms improvement of the combined treatments versus individual components as well as the long term bronchodilation comparison between AB 400 μg and TIO 18 μg in minimizing the risk of COPD exacerbations in current or former smokers, aged ≥40 in symptomatic COPD patients.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease

Keywords

  • Safety
  • Efficacy
  • Aclidinium bromide
  • Formoterol fumarate
  • Tiotropium
  • Bronchodilation
  • COPD
04

Who can participate

Ages eligible
40 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult male or non-pregnant, non-lactating female patients aged ≥40.
  • Patients with diagnosis of moderate to very severe stable : post-bronchodilator \< 80% of the predicted normal and post-bronchodilator FEV1/FVC \< 70% at Screening Visit.
  • Symptomatic patients with a CAT score ≥10 at Screening and Randomization visit (Visits 1 and 2).
  • Current or former-smokers, with a smoking history of ≥ 10 pack-years.
  • Patients able to perform acceptable and repeatable pulmonary function testing for FEV1 according to the American Thoracic Society (ATS)/European Respiratory Society (ERS) 2005 criteria at Visit 1.
  • Patients eligible and able to participate in the study and who had signed an Form prior to initiation of any study-related procedures.

Exclusion criteria

Exclusion Criteria:

  • Involvement in the planning and/or conduct of the study (applies to AstraZeneca staff and/or site staff), or patients employed by or relatives of the employees of the site or sponsor.
  • Previous randomization in the present study D6571C00001.
  • Patients with predominant asthma.
  • Any respiratory tract infection (including the upper respiratory tract) or exacerbation (including the mild COPD exacerbation) within 6 weeks prior to screening or during the run-in period.
  • Patients hospitalized for a COPD exacerbation (an emergency room visit for longer than 24 hours is considered a hospitalization) within 3 months prior to Screening Visit.
  • respiratory conditions other than COPD.
  • Patients who in the Investigator's opinion may need to start a pulmonary rehabilitation program during the study and/or patients who started/finished it within 3 months prior to Screening.
  • Use of long-term oxygen therapy (≥ 15 hours/day).
  • Patients who do not maintain regular day/night, waking/sleeping cycles including night shift workers.
  • Clinically significant cardiovascular conditions.
  • Patients with uncontrolled Type I or Type II diabetes, uncontrolled hypo-or hyperthyroidism, hypokalaemia, or hyperadrenergic state, uncontrolled hypertension.
  • Patients with history of long syndrome or whose QTc (calculated according to Fridericia's Formula QTc=QT/RR1/3) > 470 ms as indicated in the centralised reading report assessed at Screening.
  • Patients with clinically significant abnormalities in the laboratory tests, parameters (other than QTc) or in the physical examination at Screening Visit that might comprise patient safety.
  • Patient with known non-controlled history of infection with and/or active hepatitis.
  • Patient with a history of reaction to inhaled medication or any component thereof, including paradoxical bronchospasm.
  • Patients with known narrow-angle glaucoma, symptomatic bladder neck obstruction, acute urinary retention or symptomatic non-stable prostate hypertrophy.
  • History of of any organ system (including lung cancer), treated or untreated, within the past 5 years other than basal or squamous cell skin cancer.
  • Patients with any other serious or uncontrolled physical or mental dysfunction.
  • Patients with a history (within 2 years prior to screening) of drug and/or alcohol abuse that may prevent study compliance based on the Investigator judgment.
  • Patients unlikely to be cooperative or that cannot comply with the study procedures.
  • Patients treated with any drug within 30 days (or 6 half-lives, whichever is longer) prior to Screening.
  • Patients who intended to use any concomitant medication not permitted by this protocol or who had not undergone the required for a particular prohibited medication.
  • Patients unable to give consent, or patients of consenting age but under guardianship, or vulnerable patients. Patients who demonstrate \< 80% compliance with the electronic diary during the run-in period.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,595 participants (actual)

Study arms

  • Experimental
    AB/FF 400/12 μg BID

    Participants were administered AB/FF 400/12 μg via Pressair®/Genuair® inhaler twice daily for 24 weeks of treatment.

    Drug: Aclidinium bromide 400 μg/Formoterol Fumarate 12 μg (AB/FF 400/12 μg) · Other: Placebo to AB/FF 400/12 μg, AB 400 μg and FF 12 μg

  • Experimental
    AB 400 μg BID

    Participants were administered AB 400 μg via Pressair®/Genuair® inhaler twice daily for 24 weeks of treatment.

    Drug: Aclidinium bromide 400 μg (AB 400 μg) · Other: Placebo to AB/FF 400/12 μg, AB 400 μg and FF 12 μg

  • Experimental
    FF 12 μg BID

    Participants were administered FF 12 μg via Pressair®/Genuair® inhaler twice daily for 24 weeks of treatment.

    Drug: Formoterol fumarate 12 μg (FF 12 μg) · Other: Placebo to AB/FF 400/12 μg, AB 400 μg and FF 12 μg

  • Experimental
    TIO 18 μg QD

    Participants were administered TIO 18 μg via Handihaler® inhale once daily for 24 weeks of treatment.

    Drug: Tiotropium 18 μg (TIO 18 μg) · Other: Placebo to TIO 18 μg

Interventions

  • DrugAclidinium bromide 400 μg/Formoterol Fumarate 12 μg (AB/FF 400/12 μg)

    Drug page: Aclidinium bromide

    Inhalation powder

    Also known as: Oral Inhalation (by Pressair®/Genuair® Dry Powder Inhaler)

  • Inhalation powder

    Also known as: Oral Inhalation (by Pressair®/Genuair® Dry Powder Inhaler)

  • Inhalation powder

    Also known as: Oral Inhalation (by Pressair®/Genuair® Dry Powder Inhaler)

  • OtherPlacebo to AB/FF 400/12 μg, AB 400 μg and FF 12 μg

    Inhalation powder

    Also known as: Oral Inhalation (by Pressair®/Genuair® Dry Powder Inhaler)

  • Powder in capsules for oral inhalation

    Also known as: Oral Inhalation (by Handihaler® Dry Powder Inhaler, DPI)

  • OtherPlacebo to TIO 18 μg

    Powder in capsules for oral inhalation

    Also known as: Oral Inhalation (by Handihaler® Dry Powder Inhaler, DPI)

06

What researchers measure

Primary outcomes

  1. Change From Baseline in 1-hour Morning Post-dose Dose Forced Expiratory Volume in 1 Second (FEV1) of AB/FF 400/12 μg Compared to AB 400 μg at Week 24

    To assess the bronchodilatory effect by evaluating the mean changes from baseline in FEV1 at 1 hour post-dose of AB/FF 400/12 µg compared to AB 400 μg after administration of oral inhalation powder BID via DIP to participants with COPD. Baseline was defined as the average of the two FEV1 values measured just prior to the administration of the first dose of investigational product (IP) at randomization Visit. If one of the two was missing, then the available one would be used as baseline value.

    Time frame: At baseline 1-hour postdose and Week 24

  2. Change From Baseline in Morning Predose (Trough) FEV1 of AB/FF 400/12 μg Compared to FF 12 μg at Week 24

    To assess the bronchodilatory effect by evaluating the mean changes from baseline in FEV1 in morning pre-dose (trough) of AB/FF 400/12 µg compared to FF 12 μg after administration of oral inhalation powder BID via DPI to participants with COPD. Morning pre-dose (trough) FEV1 was defined as the average of the corresponding -30 minute and 0 minute before the morning study medication at Week 24. If one time-point was missing then the available one would be used as morning pre-dose.

    Time frame: At baseline morning predose and Week 24

  3. Change From Baseline in Morning Predose (Trough) FEV1 at Week 24 Comparing AB 400 μg Versus TIO 18 μg to Demonstrate Non-inferiority

    To assess the non-inferior bronchodilatory effect by evaluating the mean changes from baseline in FEV1 in morning pre-dose (trough)of AB 400 µg compared to TIO 18 μg after administration of oral inhalation powder BID via DPI to participants with COPD.

    Time frame: At baseline morning predose and Week 24

Secondary outcomes

  1. Change From Baseline in Normalized Area Under Curve 3hours Post-dose (nAUC0-3/3h) FEV1 of AB/FF 400/12 μg Compared to AB 400 μg and and FF 12 μg at Week 24

    To assess the bronchodilatory effect by evaluating the mean changes from baseline in nAUC0-3/3h FEV1 of AB/FF 400/12 µg compared to AB 400 μg and and FF 12 μg after administration of oral inhalation powder BID via DPI to participants with COPD.

    Time frame: At Day 1 and Day 169

  2. Responder (Number of Participants) Analysis of St. George's Respiratory Questionnaire (SGRQ) Total Score With AB/FF 400/12 μg Versus AB 400 μg and FF 12 μg.

    SGRQ was a A standardized self-completed tool used to measure impaired health and perceived well-being ("quality of life") in respiratory diseases. The questionnaire contained 50 items divided into 3 (symptoms, activity and impacts) dimensions. Each of the three dimensions of the questionnaire is scored separately in the range from 0 to 100%, zero score indicating no impairment of life quality. A summary score utilizing responses to all items is the total SGRQ score which also ranges from 0 to 100%. The SGRQ scores are calculated using weights attached to each item of the questionnaire which provides an estimate of the distress associated with the symptoms or state described in each item. Higher scores indicate poorer health. A decrease of at least 4 units in the SGRQ total score has been established as the criterion for minimal meaningful improvement. SGRQ responders will be those with a decrease in SGRQ total score of at least 4 units from baseline.

    Time frame: At baseline and Week 24

07

Results

Posted Nov 9, 2018

Participant flow

Study was conducted on participants with stable chronic obstructive pulmonary disease (COPD), in 11 countries: United States (US), Germany, Poland, Hungary, Bulgaria, Ukraine, United Kingdom (UK), Czech Republic, Spain, Israel \& Russia (was not finally started). First participant enrolled was 05 July 2016 \& participant last visit was 08 June 2017

Participant flow — Overall Study
MilestoneAclidinium Bromide (AB)/Formoterol Fumarate (FF) 400/12 μgAB 400 μgFF 12 μgTiotropium (TIO) 18 μg
Started317478320479
Completed treatment and follow-up279405267403
Completed279405267405
Not completed38735374
Withdrew: Adverse event11221414
Withdrew: Protocol violation7548
Withdrew: Lost to follow-up1522
Withdrew: Lack of efficacy791420
Withdrew: Withdrawal by subject41467
Withdrew: Progressive disease6151318
Withdrew: Reason not mentioned2305

Outcome measures

PrimaryChange From Baseline in 1-hour Morning Post-dose Dose Forced Expiratory Volume in 1 Second (FEV1) of AB/FF 400/12 μg Compared to AB 400 μg at Week 24

To assess the bronchodilatory effect by evaluating the mean changes from baseline in FEV1 at 1 hour post-dose of AB/FF 400/12 µg compared to AB 400 μg after administration of oral inhalation powder BID via DIP to participants with COPD. Baseline was defined as the average of the two FEV1 values measured just prior to the administration of the first dose of investigational product (IP) at randomization Visit. If one of the two was missing, then the available one would be used as baseline value.

Time frame:
At baseline 1-hour postdose and Week 24
Reported as:
Least squares mean · Litres
Change From Baseline in 1-hour Morning Post-dose Dose Forced Expiratory Volume in 1 Second (FEV1) of AB/FF 400/12 μg Compared to AB 400 μg at Week 24
LitresAB/FF 400/12 μgAB 400 μgFF 12 μgTIO 18 μg
Change From Baseline in 1-hour Morning Post-dose Dose Forced Expiratory Volume in 1 Second (FEV1) of AB/FF 400/12 μg Compared to AB 400 μg at Week 240.253 ± 0.0130.169 ± 0.0110.168 ± 0.0130.161 ± 0.011
Statistical analysis
  • AB/FF 400/12 μg vs AB 400 μg · Mixed model for repeated measures · p = <0.0001 · Ls mean difference: 0.084 · 95% CI 0.051 to 0.117
PrimaryChange From Baseline in Morning Predose (Trough) FEV1 of AB/FF 400/12 μg Compared to FF 12 μg at Week 24

To assess the bronchodilatory effect by evaluating the mean changes from baseline in FEV1 in morning pre-dose (trough) of AB/FF 400/12 µg compared to FF 12 μg after administration of oral inhalation powder BID via DPI to participants with COPD. Morning pre-dose (trough) FEV1 was defined as the average of the corresponding -30 minute and 0 minute before the morning study medication at Week 24. If one time-point was missing then the available one would be used as morning pre-dose.

Time frame:
At baseline morning predose and Week 24
Reported as:
Least squares mean · Litres
Change From Baseline in Morning Predose (Trough) FEV1 of AB/FF 400/12 μg Compared to FF 12 μg at Week 24
LitresAB/FF 400/12 μgAB 400 μgFF 12 μgTIO 18 μg
Change From Baseline in Morning Predose (Trough) FEV1 of AB/FF 400/12 μg Compared to FF 12 μg at Week 240.080 ± 0.0140.066 ± 0.0120.025 ± 0.0140.060 ± 0.012
Statistical analysis
  • AB/FF 400/12 μg vs FF 12 μg · Mixed model for repeated measures · p = 0.0009 · Ls mean difference: 0.055 · 95% CI 0.023 to 0.088
PrimaryChange From Baseline in Morning Predose (Trough) FEV1 at Week 24 Comparing AB 400 μg Versus TIO 18 μg to Demonstrate Non-inferiority

To assess the non-inferior bronchodilatory effect by evaluating the mean changes from baseline in FEV1 in morning pre-dose (trough)of AB 400 µg compared to TIO 18 μg after administration of oral inhalation powder BID via DPI to participants with COPD.

Time frame:
At baseline morning predose and Week 24
Reported as:
Least squares mean · Litres
Change From Baseline in Morning Predose (Trough) FEV1 at Week 24 Comparing AB 400 μg Versus TIO 18 μg to Demonstrate Non-inferiority
LitresAB 400 μgTIO 18 μg
Change From Baseline in Morning Predose (Trough) FEV1 at Week 24 Comparing AB 400 μg Versus TIO 18 μg to Demonstrate Non-inferiority0.064 ± 0.0130.057 ± 0.013
Statistical analysis
  • AB 400 μg vs TIO 18 μg · Mixed model for repeated measures · p = 0.6377 · Ls mean difference: 0.007 · 95% CI -0.021 to 0.035
SecondaryChange From Baseline in Normalized Area Under Curve 3hours Post-dose (nAUC0-3/3h) FEV1 of AB/FF 400/12 μg Compared to AB 400 μg and and FF 12 μg at Week 24

To assess the bronchodilatory effect by evaluating the mean changes from baseline in nAUC0-3/3h FEV1 of AB/FF 400/12 µg compared to AB 400 μg and and FF 12 μg after administration of oral inhalation powder BID via DPI to participants with COPD.

Time frame:
At Day 1 and Day 169
Reported as:
Least squares mean · Litres
Change From Baseline in Normalized Area Under Curve 3hours Post-dose (nAUC0-3/3h) FEV1 of AB/FF 400/12 μg Compared to AB 400 μg and and FF 12 μg at Week 24
LitresAB/FF 400/12 μgAB 400 μgFF 12 μgTIO 18 μg
Change From Baseline in Normalized Area Under Curve 3hours Post-dose (nAUC0-3/3h) FEV1 of AB/FF 400/12 μg Compared to AB 400 μg and and FF 12 μg at Week 240.237 ± 0.0130.162 ± 0.0100.149 ± 0.0130.151 ± 0.010
Statistical analysis
  • AB/FF 400/12 μg vs AB 400 μg · Mixed model for repeated measures · p = <0.0001 · Ls mean difference: 0.075 · 95% CI 0.043 to 0.107
  • AB/FF 400/12 μg vs FF 12 μg · Mixed model for repeated measures · p = <0.0001 · Ls mean difference: 0.087 · 95% CI 0.052 to 0.122
SecondaryResponder (Number of Participants) Analysis of St. George's Respiratory Questionnaire (SGRQ) Total Score With AB/FF 400/12 μg Versus AB 400 μg and FF 12 μg.

SGRQ was a A standardized self-completed tool used to measure impaired health and perceived well-being ("quality of life") in respiratory diseases. The questionnaire contained 50 items divided into 3 (symptoms, activity and impacts) dimensions. Each of the three dimensions of the questionnaire is scored separately in the range from 0 to 100%, zero score indicating no impairment of life quality. A summary score utilizing responses to all items is the total SGRQ score which also ranges from 0 to 100%. The SGRQ scores are calculated using weights attached to each item of the questionnaire which provides an estimate of the distress associated with the symptoms or state described in each item. Higher scores indicate poorer health. A decrease of at least 4 units in the SGRQ total score has been established as the criterion for minimal meaningful improvement. SGRQ responders will be those with a decrease in SGRQ total score of at least 4 units from baseline.

Time frame:
At baseline and Week 24
Reported as:
Count of participants · Participants
Responder (Number of Participants) Analysis of St. George's Respiratory Questionnaire (SGRQ) Total Score With AB/FF 400/12 μg Versus AB 400 μg and FF 12 μg.
ParticipantsAB/FF 400/12 μgAB 400 μgFF 12 μgTIO 18 μg
Number of responders -Yes130188128197
Number of responders- NO140195130192
Statistical analysis
  • AB/FF 400/12 μg vs AB 400 μg · Logistic random-effect model · p = 0.8714 · Odds ratio: 0.96 · 95% CI 0.61 to 1.51
  • AB/FF 400/12 μg vs FF 12 μg · Logistic random-effect model · p = 0.8873 · Odds ratio: 0.97 · 95% CI 0.59 to 1.58

Adverse events

Collected over From time of signature of the ICF throughout the treatment period and including the follow-up period (14 days after the last study drug administration). Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AB/FF 400/12 μg1/314 (0.3%)23/314 (7.3%)173/314 (55.1%)
AB 400 μg1/475 (0.2%)41/475 (8.6%)222/475 (46.7%)
FF 12 μg4/319 (1.3%)22/319 (6.9%)178/319 (55.8%)
TIO 18 μg2/475 (0.4%)37/475 (7.8%)241/475 (50.7%)
Most frequent serious events
Showing 10 of 85
Most frequent serious events
EventAB/FF 400/12 μgAB 400 μgFF 12 μgTIO 18 μg
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders7/31411/47510/31914/475
PneumoniaInfections and infestations4/3143/4751/3192/475
Myocardial infarctionCardiac disorders0/3140/4750/3193/475
Cardiac failure acuteCardiac disorders0/3142/4750/3190/475
Cardiac failure congestiveCardiac disorders0/3142/4750/3190/475
Atrial fibrillationCardiac disorders0/3141/4750/3192/475
AppendicitisInfections and infestations1/3140/4750/3190/475
SepsisInfections and infestations1/3140/4750/3190/475
Angina pectorisCardiac disorders1/3140/4750/3191/475
Atrial tachycardiaCardiac disorders1/3140/4750/3190/475
Most frequent other events
Showing 10 of 13
Most frequent other events
EventAB/FF 400/12 μgAB 400 μgFF 12 μgTIO 18 μg
Chronic obstructive pulmonaryRespiratory, thoracic and mediastinal disorders49/31479/47558/31961/475
NasopharyngitisInfections and infestations36/31447/47539/31964/475
HeadacheNervous system disorders16/31419/47517/31925/475
Back painMusculoskeletal and connective tissue disorders15/3147/4758/3197/475
Upper respiratory tract infectionInfections and infestations8/31413/4757/31917/475
CoughRespiratory, thoracic and mediastinal disorders6/3147/4754/31917/475
HypertensionVascular disorders7/3148/4759/3197/475
DyspnoeaRespiratory, thoracic and mediastinal disorders6/31413/4756/31912/475
SinusitisInfections and infestations8/31410/4756/3197/475
ArthralgiaMusculoskeletal and connective tissue disorders8/3144/4753/3198/475

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Aclidinium Bromide (AB)/Formoterol Fumarate (FF) 400/12 μgAB 400 μgFF 12 μgTiotropium (TIO) 18 μgTotal
Mean64.4 ± 8.564.4 ± 8.164.7 ± 8.364.0 ± 8.664.3 ± 8.4
Sex: Female, Male
Sex: Female, Male(Participants)Aclidinium Bromide (AB)/Formoterol Fumarate (FF) 400/12 μgAB 400 μgFF 12 μgTiotropium (TIO) 18 μgTotal
Female121171129199620
Male193304190276963
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Aclidinium Bromide (AB)/Formoterol Fumarate (FF) 400/12 μgAB 400 μgFF 12 μgTiotropium (TIO) 18 μgTotal
American Indian or Alaska Native01001
Asian02024
Native Hawaiian or Other Pacific Islander00000
Black or African American1728161677
White2974443034571501
More than one race00000
Unknown or Not Reported00000
08

Study locations

163 sites
  • Research Site
    Gulf Shores, Alabama 36542, United States
  • Research Site
    Phoenix, Arizona 85018, United States
  • Research Site
    Tucson, Arizona 85712, United States
  • Research Site
    Corona, California 92879, United States
  • Research Site
    Fresno, California 93702, United States
  • Research Site
    Fullerton, California 92835, United States
  • Research Site
    Lincoln, California 95648, United States
  • Research Site
    San Diego, California 92120, United States
  • Research Site
    Waterbury, Connecticut 06708, United States
  • Research Site
    Clearwater, Florida 33765, United States
  • Research Site
    Edgewater, Florida 32132, United States
  • Research Site
    Hollywood, Florida 33021, United States
  • Research Site
    Homestead, Florida 33030, United States
  • Research Site
    Miami Lakes, Florida 33016, United States
  • Research Site
    Miami, Florida 33144, United States
  • Research Site
    Miami, Florida 33186, United States
  • Research Site
    Ormond Beach, Florida 32174, United States
  • Research Site
    Port Orange, Florida 32129, United States
  • Research Site
    Saint Petersburg, Florida 33704, United States
  • Research Site
    Saint Petersburg, Florida 33709, United States
  • Research Site
    Sarasota, Florida 34233, United States
  • Research Site
    Tampa, Florida 33603, United States
  • Research Site
    Winter Park, Florida 32789, United States
  • Research Site
    Blue Ridge, Georgia 30513, United States
  • Research Site
    Woodstock, Georgia 30189, United States
  • Research Site
    Chicago, Illinois 60602, United States
  • Research Site
    Portage, Indiana 46368, United States
  • Research Site
    Lafayette, Louisiana 70508, United States
  • Research Site
    Fall River, Massachusetts 02720, United States
  • Research Site
    Chelsea, Michigan 48118, United States
  • Research Site
    Farmington Hills, Michigan 48336, United States
  • Research Site
    Troy, Michigan 48085, United States
  • Research Site
    Edina, Minnesota 55435, United States
  • Research Site
    Fridley, Minnesota 55432, United States
  • Research Site
    Minneapolis, Minnesota 55407, United States
  • Research Site
    Woodbury, Minnesota 55125, United States
  • Research Site
    Saint Charles, Missouri 63301, United States
  • Research Site
    Saint Louis, Missouri 63117, United States
  • Research Site
    Saint Louis, Missouri 63141, United States
  • Research Site
    Fremont, Nebraska 68025, United States
  • Research Site
    Omaha, Nebraska 68114, United States
  • Research Site
    Omaha, Nebraska 68134, United States
  • Research Site
    Las Vegas, Nevada 89102, United States
  • Research Site
    Bronx, New York 10455, United States
  • Research Site
    Brooklyn, New York 11230, United States
  • Research Site
    Buffalo, New York 14215, United States
  • Research Site
    New York, New York 10036, United States
  • Research Site
    Rochester, New York 14618, United States
  • Research Site
    Charlotte, North Carolina 28207, United States
  • Research Site
    Charlotte, North Carolina 28277, United States
  • Research Site
    Gastonia, North Carolina 28054, United States
  • Research Site
    Wilmington, North Carolina 28401, United States
  • Research Site
    Canton, Ohio 44718, United States
  • Research Site
    Cincinnati, Ohio 45231, United States
  • Research Site
    Cincinnati, Ohio 45242, United States
  • Research Site
    Cincinnati, Ohio 45246, United States
  • Research Site
    Columbus, Ohio 43207, United States
  • Research Site
    Columbus, Ohio 43215, United States
  • Research Site
    Dublin, Ohio 43016, United States
  • Research Site
    Grove City, Ohio 43123, United States
  • Research Site
    Edmond, Oklahoma 73034, United States
  • Research Site
    Midwest City, Oklahoma 73110, United States
  • Research Site
    Oklahoma City, Oklahoma 73104, United States
  • Research Site
    Medford, Oregon 97504, United States
  • Research Site
    Altoona, Pennsylvania 16602, United States
  • Research Site
    Pittsburgh, Pennsylvania 15243, United States
  • Research Site
    Wyomissing, Pennsylvania 19610, United States
  • Research Site
    East Providence, Rhode Island 02914, United States
  • Research Site
    Columbia, South Carolina 29204, United States
  • Research Site
    Gaffney, South Carolina 29340, United States
  • Research Site
    Mount Pleasant, South Carolina 29464, United States
  • Research Site
    Spartanburg, South Carolina 29303, United States
  • Research Site
    Union, South Carolina 29379, United States
  • Research Site
    Arlington, Texas 76012, United States
  • Research Site
    Baytown, Texas 77521, United States
  • Research Site
    Boerne, Texas 78006, United States
  • Research Site
    Dallas, Texas 75225, United States
  • Research Site
    Fort Worth, Texas 76104, United States
  • Research Site
    Houston, Texas 77074, United States
  • Research Site
    Lewisville, Texas 75067, United States
  • Research Site
    McKinney, Texas 75069, United States
  • Research Site
    Tomball, Texas 77375, United States
  • Research Site
    Midvale, Utah 84047, United States
  • Research Site
    Abingdon, Virginia 24210, United States
  • Research Site
    Newport News, Virginia 23606, United States
  • Research Site
    Dimitrovgrad, 6400, Bulgaria
  • Research Site
    Gabrovo, 5300, Bulgaria
  • Research Site
    Roman, 3130, Bulgaria
  • Research Site
    Ruse, 7002, Bulgaria
  • Research Site
    Sevlievo, 5400, Bulgaria
  • Research Site
    Sliven, 8800, Bulgaria
  • Research Site
    Sofia, 1002, Bulgaria
  • Research Site
    Sofia, 1431, Bulgaria
  • Research Site
    Stara Zagora, 6003, Bulgaria
  • Research Site
    Vidin, 3700, Bulgaria
  • Research Site
    Jaromer, 544 01, Czechia
  • Research Site
    Jindrichuv Hradec, 377 01, Czechia
  • Research Site
    Praha 8, 182 00, Czechia
  • Research Site
    Rokycany, 33722, Czechia
  • Research Site
    Strakonice, 38601, Czechia

Showing the first 100 of 163 sites across 10 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Sethi S, Kerwin E, Watz H, Ferguson GT, Mroz RM, Segarra R, Molins E, Jarreta D, Garcia Gil E. AMPLIFY: a randomized, Phase III study evaluating the efficacy and safety of aclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPD. Int J Chron Obstruct Pulmon Dis. 2019 Mar 22;14:667-682. doi: 10.2147/COPD.S189138. eCollection 2019. PubMed 30962681 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2016 to primary completion in Jun 2017, 11 months.

Results were first posted in Nov 2018, 1 year 5 months after primary completion.

Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's 11 months is below that.

Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2016
First posted
Jun 13, 2016
StartActual
Jul 5, 2016
Primary completionActual
Jun 8, 2017
CompletionActual
Jun 8, 2017
Results first posted
Nov 9, 2018
Last update
Nov 9, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 9, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02796677
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jun 13, 2016
Start date
Jul 5, 2016
Primary completion
Jun 8, 2017
Completion
Jun 8, 2017
Results posted
Nov 9, 2018
Last update
Nov 9, 2018

Study contacts

Sanjay Sethi
principal investigator · 3495 Bailey Ave , Buffalo NY14215, USA

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Aclidinium bromide · Formoterol · Tiotropium

Start the discussion